Saccharo, founded in 2017 by Sherry Martin-Moe and Gregory Moe in Oakland, California, is a therapeutic biotech start-up focused on immuno-oncology. The company develops innovative treatments for cancer and other novel diseases, leveraging a unique polysaccharide-based immune shielding pathway discovered by its co-founder. Saccharo’s approach allows for multiple killing effects, a broad therapeutic window, and applications across various cancers, aiming to revolutionize cancer therapy with a predicted safety profile.
Notable figures affiliated with Saccharo include its founders, Sherry Martin-Moe and Gregory Moe, who bring significant expertise to the company. Saccharo has made key strides in the preclinical stage, developing a promising pipeline of cancer therapies. The discovery of the polysaccharide mechanism has positioned Saccharo as a pioneer in the field, potentially transforming cancer treatment and offering new hope for patients worldwide.
